



UK medical press release

**New MOVICOL<sup>®</sup> Liquid (macrogol 3350, sodium hydrogen carbonate, sodium chloride, potassium chloride) formulation provides added benefits to both patients and healthcare professionals**

*New formulation is ready in seconds with no stirring or residue*

**22 June 2011** – Today, Norgine Pharmaceuticals Limited launches MOVICOL<sup>®</sup> Liquid, a new formulation of its leading chronic constipation treatment MOVICOL<sup>®</sup>. With all the same benefits in treating chronic constipation as the established powder formulation – effective, well tolerated and cost effective - MOVICOL<sup>®</sup> Liquid is even easier and faster for healthcare professionals to prepare and administer, with no stirring and no unpleasant residue.<sup>1-6</sup>

Administering MOVICOL<sup>®</sup> Liquid is easy – you simply add 100 ml water to 25 ml of MOVICOL<sup>®</sup> Liquid and it can be taken anytime, with or without food or drink.<sup>6</sup> It mixes in seconds with no stirring required, which is ideal for healthcare professionals on busy wards or in elderly and palliative care settings.<sup>6</sup> This is also important for elderly patients with dexterity issues who find stirring difficult. MOVICOL<sup>®</sup> Liquid leaves no unpleasant residue making it more palatable for patients to take.

MOVICOL<sup>®</sup> Liquid comes in a 500 ml plastic bottle, fitted with its own convenient measuring device which sits flush against the bottle cap.<sup>6</sup> It can be used for up to 30 days once opened and does not require refrigeration. Each bottle contains 20 doses.<sup>6</sup>

-Ends-

**References:**

1. Attar A *et al.* Gut 1999; 44: 226-230
2. Gruss HJ, Teucher T. Gen Pract 1999; 21(16): 1342-1350
3. Guest JF, Varney SJ. Clin Drug Invest 2004; 24(12): 719-729
4. Taylor RR, Guest JF. Aliment Pharmacol Ther 2009; 31: 302-312
5. Christie AH *et al.* Pharmacoeconomics 2002; 20(1): 49-60
6. MOVICOL<sup>®</sup> Liquid Summary of Product Characteristics

REFER TO FULL SUMMARY OF PRODUCT CHARACTERISTICS (SmPC) BEFORE PRESCRIBING

**Presentation:**

A clear, concentrated liquid, which is diluted in water to make an orange flavoured drink.

Each 25 ml of MOVICOL Liquid is diluted in 100 ml of water before use and contains the following active ingredients: 13.125 g macrogol (polyethylene glycol) 3350, 178.5 mg sodium hydrogen carbonate, 350.7 mg sodium chloride and 46.6mg potassium chloride.

**Uses:**

Treatment of chronic constipation.

**Dosage and administration:**

Adults, adolescents and the elderly: 25 ml diluted in 100 ml of water 1-3 times daily in divided doses, according to individual response.

For extended use, the dose can be adjusted down to 1 or 2 doses per day, each consisting of 25 ml diluted in 100 ml of water.

Extended use may be necessary in patients with severe chronic or resistant constipation, secondary to multiple sclerosis or Parkinson's Disease, or induced by regular constipating medicine, in particular opioids and antimuscarinics.

A course of MOVICOL Liquid treatment does not normally exceed 2 weeks, but can be repeated if required.

Children (below 12 years): not recommended. See MOVICOL Paediatric Plain.

**Contra-indications:**

Intestinal perforation or obstruction due to structural or functional disorders of the gut wall, ileus and severe inflammatory conditions of the intestinal tract, such as Crohn's disease, ulcerative colitis and toxic megacolon.

Hypersensitivity to the active substances or any of the excipients.

**Warnings and precautions for use:**

If patients develop any symptoms indicating shifts of fluids/electrolytes MOVICOL Liquid should be stopped immediately.

MOVICOL Liquid contains 8.125 mmol of sodium in each diluted dose of 125 ml and should be considered when administered to patients on a controlled sodium diet.

MOVICOL Liquid contains benzyl alcohol. Do not exceed the maximum recommended daily dose.

**Interactions:**

There is a possibility that the absorption of concomitantly administered medication could be transiently reduced.

**Pregnancy and lactation:**

There is insufficient data on use in pregnancy and lactation, and should only be used if considered essential.

**Undesirable effects:**

Reactions related to the gastrointestinal tract are the most common and include: abdominal pain, abdominal distension, nausea, dyspepsia, vomiting, diarrhoea, flatulence, borborygmi and anal discomfort.

Allergic reactions, including anaphylactic reaction, angioedema, dyspnoea and skin reactions can occur.

Other effects can include electrolyte disturbances, headache and peripheral oedema.

**Licensing and legal category:**

Legal Category: P. Cost: 500ml £4.45.

MA number: PL20011/0007

**For further information contact:**



Norgine Pharmaceuticals Limited  
Norgine House  
Moorhall Road  
Harefield  
Middlesex UB9 6NS  
Telephone: 01895 826606  
E-mail: [medinfo@norgine.com](mailto:medinfo@norgine.com)

MOVICOL<sup>®</sup> is a registered trademark of the NORGINE<sup>®</sup> group of companies.

**Date of preparation/revision:** MO/2379/MAY/11.

Adverse events should be reported. Reporting forms and information can be found at [www.yellowcard.gov.uk](http://www.yellowcard.gov.uk). Adverse events should also be reported to Medical Information at Norgine Pharmaceuticals Ltd on 01895 826606